Ionis Pharmaceuticals Stock Price

0.00 (0.0%)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ionis Pharmaceuticals Inc IONS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 37.69 04:00:31
Open Price Low Price High Price Close Price Prev Close
Bid Price Ask Price Spread News
36.70 38.81 2.11 - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 37.69 USD

Ionis Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.31B 140.96M 118.92M $ 729.26M $ -534.11M -3.16 -10.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -158.00 0.50%

more financials information »

Ionis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IONS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week36.8837.9436.3237.461,267,0140.812.2%
1 Month35.82538.6334.4336.771,997,5601.875.21%
3 Months44.9147.8734.4338.891,833,537-7.22-16.08%
6 Months58.6864.3734.4345.321,457,644-20.99-35.77%
1 Year58.7664.3734.4347.951,195,208-21.07-35.86%
3 Years42.5188.707534.4354.941,089,174-4.82-11.34%
5 Years22.8288.707520.4949.581,266,60214.8765.16%

Ionis Pharmaceuticals Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Your Recent History
Ionis Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.